Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.72 |
| ▸ | FNTA | P49354 | 9/20 | 0.46 |
| ▸ | FNTB | P49356 | 7/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455692 | 1.00 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| Phosphoric Acid SCHEMBL27686050 | 0.98 | BTN3A1 (0.70) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL30169833 | 0.89 | BTN3A1 (0.60) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL23455691 | 0.84 | BTN3A1 (0.63) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL83423 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL14387716 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL254662 | 0.84 | BTN3A1 (1.00) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL13485664 | 0.83 | BTN3A1 (0.62) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL8439565 | 0.83 | BTN3A1 (0.52) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL13485448 | 0.82 | BTN3A1 (0.61) | BTN3A1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260117263-A1 | GENETICALLY ENGINEERED PEPTIDE SUPERSTRUCTURE AND MICROBE FOR PRODUCTION OF ISOPRENE AND METHOD OF PRODUCTION THEREOF | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260117262-A1 | GENETICALLY ENGINEERED MICROBE FOR THE PRODUCTION OF TERPENES AND METHOD OF PRODUCTION THEREOF | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260117264-A1 | GENETICALLY ENGINEERED MICROBE FOR PRODUCTION OF ISOPRENE FROM A CARBON SOURCE AND METHOD OF PRODUCTION THEREOF | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4704975-A1 | NOVEL PHOSPHOANTIGEN PRODRUG COMPOUND AND USE THEREOF | University College Cardiff Consultants, Ltd. (GB) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024231319-A1 | NOVEL PHOSPHOANTIGEN PRODRUG COMPOUND AND USE THEREOF | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2024-11-14 | — | — | WO | disclosed |
| EP-4458412-A1 | NOVEL PHOSPHOANTIGEN PRODRUG COMPOUND AND USE THEREOF | University College Cardiff Consultants, Ltd. (GB) | 2024-11-06 | — | — | EP | disclosed |
| US-11999968-B2 | Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same | FULLHOPE BIOMEDICAL CO., LTD (TW) | 2024-06-04 | — | — | US | disclosed |
| CN-117794581-A | Conjugates comprising phosphoantigen and their use in therapy | 拜奥迪斯私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230383318-A1 | METHODS AND SYSTEMS FOR CHEMOAUTOTROPHIC PRODUCTION OF ORGANIC COMPOUNDS | GINKGO BIOWORKS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2006034286-A2 | ISOPENTENYL TRANSFERASE SEQUENCES AND METHODS OF USE | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060064786-A1 | Isopentenyl transferase sequences and methods of use | PIONEER HI-BRED INTERNATIONAL, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060031963-A1 | Method for the production of ketocarotinoids in flower petals on plants | SUNGENE GMBH & CO. KGAA (DE) | 2006-02-09 | — | — | US | disclosed |
| US-20050281909-A1 | Use of astaxanthin-containing plants or parts of plants of the genus tagetes as feedstuffs | SUNGENE GMBH & CO., KGAA (DE) | 2005-12-22 | — | — | US | disclosed |
| WO-2005102385-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| EP-1546334-A2 | TOCOPHEROL BIOSYNTHESIS RELATED GENES AND USES THEREOF | Monsanto Technology LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004013312-A2 | TOCOPHEROL BIOSYNTHESIS RELATED GENES AND USES THEREOF | MONSANTO TECHNOLOGY, LLC (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1356033-A2 | METHYL-D-ERYTHRITOL PHOSPHATE PATHWAY GENES | Monsanto Technology LLC (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002012478-A2 | METHYL-D-ERYTHRITOL PHOSPHATE PATHWAY GENES | MONSANTO TECHNOLOGY, LLC (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117263-A1 | GENETICALLY ENGINEERED PEPTIDE SUPERSTRUCTURE AND MICROBE FOR PRODUCTION OF ISOPRENE AND METHOD OF PRODUCTION THEREOF | FDPS, COASY, DHPS | BTN3A1 3611/4885FNTA 69/4885FNTB 30/4885 |
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | ERG28, DIMT1, MSMO1 | BTN3A1 4591/4885FNTA 82/4885FNTB 32/4885 |
| US-20260117264-A1 | GENETICALLY ENGINEERED MICROBE FOR PRODUCTION OF ISOPRENE FROM A CARBON SOURCE AND METHOD OF PRODUCTION THEREOF | COASY, ACADM, ADH5 | BTN3A1 4443/4885FNTA 182/4885FNTB 135/4885 |
| US-20260117262-A1 | GENETICALLY ENGINEERED MICROBE FOR THE PRODUCTION OF TERPENES AND METHOD OF PRODUCTION THEREOF | COASY, ACSL1, ACSL6 | BTN3A1 4134/4885FNTA 17/4885FNTB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.